Literature DB >> 22278019

TWEAK (tumor necrosis factor-like weak inducer of apoptosis) activates CXCL16 expression during renal tubulointerstitial inflammation.

María Concepción Izquierdo1, Ana B Sanz, Sergio Mezzano, Julia Blanco, Susana Carrasco, María Dolores Sanchez-Niño, Alberto Benito-Martín, Marta Ruiz-Ortega, Jesús Egido, Alberto Ortiz.   

Abstract

TWEAK (tumor necrosis factor-like weak inducer of apoptosis) is a TNF superfamily cytokine that activates the fibroblast growth factor-inducible 14 (Fn14) receptor. Transcriptional analysis of experimental kidney tubulointerstitial inflammation showed a correlation between an upregulation of the mRNA for the transmembrane chemokine CXCL16, a T-cell chemoattractant, and Fn14 activation. Exogenous TWEAK increased mouse kidney CXCL16 expression and T-lymphocyte infiltration in vivo, processes inhibited by the NF-κB inhibitor parthenolide. Tubular cell CXCL16 was increased in a nephrotoxic tubulointerstitial inflammation model and neutralizing anti-TWEAK antibodies decreased this CXCL16 expression and lymphocyte infiltration. In human kidney biopsies with tubulointerstitial inflammation, tubular cell CXCL16 and Fn14 expressions were associated with inflammatory infiltrates. TWEAK upregulated CXCL16 mRNA expression in cultured renal tubular cells in an NF-κB-dependent manner and increased soluble and cellular CXCL16 protein. CXCL16 modestly promoted the expression of cytokines in tubular cells expressing its receptor (CXCR6) and appeared to synergize with TWEAK to promote an inflammatory response; however, it did not modulate tubular cell proliferation or survival. Thus, TWEAK upregulates the expression of the chemokine CXCL16 in tubular epithelium and this may contribute to kidney tubulointerstitial inflammation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22278019     DOI: 10.1038/ki.2011.475

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  24 in total

Review 1.  Role of TWEAK in lupus nephritis: a bench-to-bedside review.

Authors:  Jennifer S Michaelson; Nicolas Wisniacki; Linda C Burkly; Chaim Putterman
Journal:  J Autoimmun       Date:  2012-06-22       Impact factor: 7.094

2.  The gender-specific association of CXCL16 A181V gene polymorphism with susceptibility to multiple sclerosis, and its effects on PBMC mRNA and plasma soluble CXCL16 levels: preliminary findings.

Authors:  Ljiljana Stojković; Aleksandra Stanković; Tamara Djurić; Evica Dinčić; Dragan Alavantić; Maja Zivković
Journal:  J Neurol       Date:  2014-05-23       Impact factor: 4.849

3.  Inflammation-activated CXCL16 pathway contributes to tubulointerstitial injury in mouse diabetic nephropathy.

Authors:  Ze-Bo Hu; Kun-Ling Ma; Yang Zhang; Gui-Hua Wang; Liang Liu; Jian Lu; Pei-Pei Chen; Chen-Chen Lu; Bi-Cheng Liu
Journal:  Acta Pharmacol Sin       Date:  2018-04-05       Impact factor: 6.150

4.  The pathogenesis of diclofenac induced immunoallergic hepatitis in a canine model of liver injury.

Authors:  Saravanakumar Selvaraj; Jung-Hwa Oh; Reinhard Spanel; Florian Länger; Hyoung-Yun Han; Eun-Hee Lee; Seokjoo Yoon; Jürgen Borlak
Journal:  Oncotarget       Date:  2017-09-23

Review 5.  Inflammation and renal fibrosis: Recent developments on key signaling molecules as potential therapeutic targets.

Authors:  Wenshan Lv; George W Booz; Yangang Wang; Fan Fan; Richard J Roman
Journal:  Eur J Pharmacol       Date:  2017-12-08       Impact factor: 4.432

6.  Effect of erythropoietin on the expression of dynamin-related protein-1 in rat renal interstitial fibrosis.

Authors:  Xian-Feng Zhao; Yan-Hong Liu; Zi-Ming Han; Y U Xu
Journal:  Exp Ther Med       Date:  2015-04-09       Impact factor: 2.447

Review 7.  TWEAK and the progression of renal disease: clinical translation.

Authors:  Ana B Sanz; M Concepcion Izquierdo; Maria Dolores Sanchez-Niño; Alvaro C Ucero; Jesus Egido; Marta Ruiz-Ortega; Adrián Mario Ramos; Chaim Putterman; Alberto Ortiz
Journal:  Nephrol Dial Transplant       Date:  2014-02       Impact factor: 5.992

8.  Serum-soluble CXCL16 in juvenile systemic lupus erythematosus: a promising predictor of disease severity and lupus nephritis.

Authors:  Arwa Mohammad Hassan; Nessma Mohamed Ahmed Farghal; Doaa Salah Hegab; Wesam Salah Mohamed; Hend Hassan Abd-Elnabi
Journal:  Clin Rheumatol       Date:  2018-07-13       Impact factor: 2.980

9.  Urine metabolomics insight into acute kidney injury point to oxidative stress disruptions in energy generation and H2S availability.

Authors:  Marta Martin-Lorenzo; Laura Gonzalez-Calero; Angeles Ramos-Barron; Maria D Sanchez-Niño; Carlos Gomez-Alamillo; Juan Manuel García-Segura; Alberto Ortiz; Manuel Arias; Fernando Vivanco; Gloria Alvarez-Llamas
Journal:  J Mol Med (Berl)       Date:  2017-10-04       Impact factor: 4.599

10.  TWEAK Signaling Pathway Blockade Slows Cyst Growth and Disease Progression in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Adrian Cordido; Laura Nuñez-Gonzalez; Julio M Martinez-Moreno; Olaya Lamas-Gonzalez; Laura Rodriguez-Osorio; Maria Vanessa Perez-Gomez; Diego Martin-Sanchez; Patricia Outeda; Marco Chiaravalli; Terry Watnick; Alessandra Boletta; Candido Diaz; Angel Carracedo; Ana B Sanz; Alberto Ortiz; Miguel A Garcia-Gonzalez
Journal:  J Am Soc Nephrol       Date:  2021-06-21       Impact factor: 14.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.